- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04022746
An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer
Multiparametric MRI and MRE Assessment of Liver Fibrosis in Patients Treated for HCC
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To evaluate the ability of magnetic resonance (MR) elastography (MRE) to detect changes in hepatocellular carcinoma (HCC) between baseline and after initial 6 weeks of treatment (change in MRE liver tumor stiffness compared to percent non-viable/necrotic tumor).
SECONDARY OBJECTIVES:
I. Correlate MRE imaging measurements with patient survival (overall survival and time to tumor progression) over 18 months.
II. Correlate MRE measurements with change in tumor size and enhancement on standard of care MR imaging sequences.
OUTLINE:
Patients undergo standard of care MRI and MRE over 30-90 minutes within 5 days of liver biopsy before receiving any medical treatment for HCC, at 6 weeks after medical treatment for HCC, and then every 12 weeks for up to 24 months.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Priya Bhosale
- Phone Number: 713-792-0221
- Email: priya.bhosale@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Principal Investigator:
- Priya R. Bhosale
-
Contact:
- Priya R. Bhosale
- Phone Number: 713-792-0221
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Liver cancer.
- Available tumor and liver parenchyma tissue (biopsy-proven HCC).
- No contraindications to MRI (such implanted ferromagnetic or pump devices, metallic fragments in eye), as indicated on our departmental MRI screening form.
- Able to undergo informed consent.
- Not pregnant.
Exclusion Criteria:
- Contraindication to MRI (including cardiac pacemaker; ferromagnetic foreign objects in the patient; metallic eye fragments; claustrophobia).
- Inability to comply with study and/or follow-up procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diagnostic (MRI/MRE)
Patients undergo standard of care MRI and MRE over 30-90 minutes within 5 days of liver biopsy before receiving any medical treatment for HCC, at 6 weeks after medical treatment for HCC, and then every 12 weeks for up to 24 months.
|
Undergo multiparametric MRI/MRE
Other Names:
Undergo multiparametric MRI/MRE
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in magnetic resonance elastography (MRE) liver tumor stiffness
Time Frame: Baseline to 6 weeks
|
Imaging measurements and percent necrosis will be summarized using mean, standard deviation (SD), and range.
Pearson correlation coefficient will be estimated between imaging measurements and percent necrosis.
|
Baseline to 6 weeks
|
Change in percent non-viable/necrotic tumor
Time Frame: Baseline to 6 weeks
|
Will be determined by pathologists using follow-up biopsy/surgery samples.
Imaging measurements and percent necrosis will be summarized using mean, SD, and range.
Pearson correlation coefficient will be estimated between imaging measurements and percent necrosis.
|
Baseline to 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 18 months
|
Cox proportional hazard model will be used to correlate imaging measurements with survival endpoints.
|
18 months
|
Time to tumor progression
Time Frame: 18 months
|
Logistic regression model will be used to correlate imaging measurements with response status.
|
18 months
|
Change in tumor size and enhancement
Time Frame: Baseline to 18 months
|
Will correlate MRE measurements with change in tumor size and enhancement on standard of care MR imaging sequences.
Linear mixed model will be used to correlate MRE imaging measurements with other tumor characteristics (e.g.
size, etc.).
|
Baseline to 18 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Priya Bhosale, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-1113
- NCI-2019-02182 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Adult Hepatocellular Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Adult Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular Carcinoma | BCLC Stage D Adult Hepatocellular Carcinoma | Localized Resectable Adult Liver... and other conditionsUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
AstraZenecaIonis Pharmaceuticals, Inc.CompletedAdvanced Adult Hepatocellular Carcinoma | Hepatocellular Carcinoma MetastaticKorea, Republic of, Taiwan, Hong Kong, Japan
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer Network; AVEO...CompletedAdvanced Adult Hepatocellular Carcinoma | Non-Resectable Hepatocellular CarcinomaUnited States
-
Shenzhen SiBiono GeneTech Co.,LtdUnknownAdvanced Adult Hepatocellular CarcinomaChina
-
GenSpera, Inc.CompletedAdvanced Adult Hepatocellular CarcinomaUnited States
Clinical Trials on Magnetic Resonance Elastography
-
Xiangya Hospital of Central South UniversityUnknownTraumatic Brain Injury
-
Mayo ClinicNational Institute on Aging (NIA)Enrolling by invitationHealthy | Alzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Assistance Publique - Hôpitaux de ParisUnknown
-
Penn State UniversityNational Institutes of Health (NIH)Completed
-
Centre hospitalier de l'Université de Montréal...Canadian Institutes of Health Research (CIHR); Centre de Recherche du Centre...CompletedHepatitis B | Hepatitis C | Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)Canada
-
University of Southern CaliforniaNational Cancer Institute (NCI)Not yet recruitingBrain NeoplasmUnited States
-
Shengjing HospitalRecruitingSpinal Cord TumorsChina
-
Hospices Civils de LyonUnknownRenal TransplantFrance
-
Shengjing HospitalRecruiting
-
Ohio State UniversityTerminated